Drug Interaction Report

Encorafenib and Enzalutamide: Interaction Details

A pharmacist-reviewed analysis of the Encorafenib and Enzalutamide interaction: the documented clinical effects, severity rating, onset, mechanism, and management considerations, with cited references throughout.

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Enzalutamide

Xtandi
+

Encorafenib

Braftovi Braftovi®
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
Updated Aug 8, 2026
Editorial policy · Data sources
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 468 documented Encorafenib interactions, 392 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
Onset
unspecified
Evidence
theoretical
Severity
Major

What happens

Reduced enzalutamide exposure, reduced efficacy of enzalutamide, reduced encorafenib exposure and reduced efficacy of encorafenib

Interaction Deep Dive

Avoid concomitant administration of enzalutamide with encorafenib (strong CYP3A4 inducer) as it may reduce enzalutamide, which may reduce the efficacy of enzalutamide2. Concomitant use of encorafenib and enzalutamide (CYP3A4 inducer) may reduce encorafenib exposure and may also reduce efficacy of encorafenib 1. If the coadministration of encorafenib cannot be avoided, increase the enzalutamide dosage from 160 mg to 240 mg orally once daily. If the coadministration of encorafenib is discontinued, reduce the enzalutamide dosage to the dosage used prior to initiation of encorafenib 2.

Why it happens (mechanism)

Induction of CYP3A4-mediated metabolism of enzalutamide; induction of CYP3A4-mediated metabolism of encorafenib

Literature reports

1 report — tap to read

a) In a drug interaction study, coadministration of enzalutamide 160 mg after multiple oral doses of rifAMPin (strong CYP3A4 inducer) decreased the AUC of enzalutamide plus N-desmethyl enzalutamide by 37% with no effect on Cmax 2.

Common questions

Can I take Encorafenib and Enzalutamide together?

Reduced enzalutamide exposure, reduced efficacy of enzalutamide, reduced encorafenib exposure and reduced efficacy of encorafenib Always confirm with your pharmacist or prescriber before making any change.

How serious is the Encorafenib and Enzalutamide interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Encorafenib or Enzalutamide need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (2)

  1. Product Information: BRAFTOVI(R) oral capsules, encorafenib oral capsules. Array BioPharma Inc (per FDA), Boulder, CO, 2024. DailyMed
  2. Product Information: XTANDI® oral capsules, oral tablets, enzalutamide oral capsules, oral tablets. Astellas Pharma US Inc (per FDA), Northbrook, IL, 2025. DailyMed
Was this write-up helpful?
Enzalutamide

Keep reading about Enzalutamide

All Enzalutamide interactions (120)
Also serious with: Colchicine Lenacapavir Oral Doravirine Lurasidone
Encorafenib

Keep reading about Encorafenib

All Encorafenib interactions (468) Encorafenib drug information
Also serious with: Piperaquine Posaconazole Pimozide Doravirine
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

Enzalutamide + Activated Charcoal Alkanna Alpine Ragwort Black Tea Boneset Borage Butterbur Cannabidiol (cbd) + 41 more
Encorafenib + Activated Charcoal American Hellebore Arsenic Cesium Ephedra Grapefruit Sida Cordifolia St. John's Wort + 143 more

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.